JPY5,646.00
1.00% day before yesterday
Tokyo, Sep 06, 08:10 am CET
ISIN
JP3475350009
Symbol
4568
Index
Sector
Industry

DAIICHI SANKYO Stock price

JPY5,646.00
+220.00 4.05% 1M
+716.00 14.52% 6M
+1,774.00 45.82% YTD
+1,425.00 33.76% 1Y
+2,856.00 102.37% 3Y
+3,296.67 140.32% 5Y
+5,029.17 815.32% 10Y
Tokyo, Closing price Fri, Sep 06 2024
-57.00 1.00%
ISIN
JP3475350009
Symbol
4568
Index
Sector
Industry

Key metrics

Market capitalization JPY10.78t
Enterprise Value JPY10.08t
P/E (TTM) P/E ratio 47.23
EV/FCF (TTM) EV/FCF 22.36
EV/Sales (TTM) EV/Sales 5.97
P/S ratio (TTM) P/S ratio 6.39
P/B ratio (TTM) P/B ratio 6.26
Dividend yield 1.06%
Last dividend (FY25) JPY60.00
Revenue growth (TTM) Revenue growth 25.06%
Revenue (TTM) Revenue JPY1.69t
EBIT (operating result TTM) EBIT JPY206.07b
Free Cash Flow (TTM) Free Cash Flow JPY450.50b
Cash position JPY805.26b
EPS (TTM) EPS JPY119.55
P/E forward 50.85
P/S forward 5.94
EV/Sales forward 5.55
Show more

Is DAIICHI SANKYO a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

DAIICHI SANKYO Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a DAIICHI SANKYO forecast:

14x Buy
88%
2x Hold
13%

Analyst Opinions

16 Analysts have issued a DAIICHI SANKYO forecast:

Buy
88%
Hold
13%

Financial data from DAIICHI SANKYO

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
1,687,027 1,687,027
25% 25%
100%
- Direct Costs 416,694 416,694
9% 9%
25%
1,270,333 1,270,333
31% 31%
75%
- Selling and Administrative Expenses 613,440 613,440
38% 38%
36%
- Research and Development Expense 388,730 388,730
13% 13%
23%
268,163 268,163
50% 50%
16%
- Depreciation and Amortization 62,092 62,092
7% 7%
4%
EBIT (Operating Income) EBIT 206,071 206,071
85% 85%
12%
Net Profit 229,101 229,101
55% 55%
14%

In millions JPY.

Don't miss a Thing! We will send you all news about DAIICHI SANKYO directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals. Its products include drugs for the field of oncology such as Trastuzumab deruxtecan, Anti-HER3-ADC, Quizartinib, Milademetan, Valemetostat, Pexidartinib, Edoxaban, Prasugel, and Microgabalin. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan.

Head office Japan
CEO Sunao Manabe
Employees 18,726
Founded 2005
Website www.daiichisankyo.co.jp

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today